Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2006;48:988-993
Published online before print September 18, 2006, doi: 10.1161/01.HYP.0000243612.02929.df
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
48/5/988    most recent
01.HYP.0000243612.02929.dfv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ryan, M. J.
Right arrow Articles by Hendrix, S. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ryan, M. J.
Right arrow Articles by Hendrix, S. T.
Related Collections
Right arrow Obesity
Right arrow Animal models of human disease
Right arrow Glucose intolerance

(Hypertension. 2006;48:988.)
© 2006 American Heart Association, Inc.


Original Articles

Insulin Resistance and Obesity in a Mouse Model of Systemic Lupus Erythematosus

Michael J. Ryan; Gerald R. McLemore, Jr; Steven T. Hendrix

From the Department of Physiology, University of Mississippi Medical Center, Jackson, Miss.

Correspondence to Michael J. Ryan, Department of Physiology and Biophysics, University of Mississippi Medical Center, 2500 North State St, Jackson, MS 39216. E-mail mjryan{at}physiology.umsmed.edu

Accumulating data indicate that metabolic syndrome is an inflammatory condition. Systemic lupus erythematosus (SLE) is an autoimmune disorder associated with nephritis and cardiovascular disease. Evidence suggests that individuals with SLE are at risk for developing insulin resistance; however, this has not been directly examined. Using an established mouse strain with SLE (NZBWF1), we examined whether SLE is associated with increased body weight and fat deposition. Mean arterial pressure was significantly increased (140±4 versus 114±2 mm Hg; n≥5) in SLE mice by 36 weeks of age compared with control mice (NZW/LacJ). Body weight in SLE mice was higher at each age compared with controls by 12%, 22%, and 34% (n>30). Visceral adipose tissue weight was increased in SLE by 44%, 74%, and 117% at 8, 20, and 36 weeks, respectively (n≥12). Plasma leptin was increased in SLE mice (8.6±1.0 versus 24.7±2.2 ng/mL; n=5), and renal and adipose tissue exhibited macrophage infiltration. Fasted insulin was higher in SLE mice (0.6±0.1 versus 1.4±0.3 ng/mL; n≥10), but fasted glucose was not different (94±5 versus 80±9; n≥9). A glucose tolerance test caused a significantly greater and longer increase in blood glucose from mice with SLE compared with control mice. Food intake was not different between control and SLE mice. However, mice with SLE demonstrated lower levels of nighttime activity than controls. These data show that the NZBWF1 strain may be an important model to study the effects of obesity and insulin resistance on SLE-associated hypertension.


Key Words: SLE • autoimmune • inflammation • insulin • adipose • leptin • glucose




This article has been cited by other articles:


Home page
J. Immunol.Home page
W. Zhao, S. G. Thacker, J. B. Hodgin, H. Zhang, J. H. Wang, J. L. Park, A. Randolph, E. C. Somers, S. Pennathur, M. Kretzler, et al.
The Peroxisome Proliferator-Activated Receptor {gamma} Agonist Pioglitazone Improves Cardiometabolic Risk and Renal Inflammation in Murine Lupus
J. Immunol., August 15, 2009; 183(4): 2729 - 2740.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
M. J. Ryan
Young Investigator Award Lecture of the APS Water and Electrolyte Homeostasis Section, 2008: The pathophysiology of hypertension in systemic lupus erythematosus
Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2009; 296(4): R1258 - R1267.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
M. Venegas-Pont, J. C. Sartori-Valinotti, C. Maric, L. C. Racusen, P. H. Glover, G. R. McLemore Jr., A. V. Jones, J. F. Reckelhoff, and M. J. Ryan
Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus
Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2009; 296(4): R1282 - R1289.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
M.-A. Cornier, D. Dabelea, T. L. Hernandez, R. C. Lindstrom, A. J. Steig, N. R. Stob, R. E. Van Pelt, H. Wang, and R. H. Eckel
The Metabolic Syndrome
Endocr. Rev., December 1, 2008; 29(7): 777 - 822.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
R. Iliescu, R. Cazan, G. R. McLemore Jr., M. Venegas-Pont, and M. J. Ryan
Renal blood flow and dynamic autoregulation in conscious mice
Am J Physiol Renal Physiol, September 1, 2008; 295(3): F734 - F740.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
A. Perciaccante, A. Fiorentini, and L. Tubani
Insulin Resistance and Obesity in a Mouse Model of Systemic Lupus Erythematosus
Hypertension, February 1, 2007; 49(2): e12 - e12.
[Full Text] [PDF]


Home page
HypertensionHome page
M. J. Ryan
Response to Insulin Resistance and Obesity in a Mouse Model of Systemic Lupus Erythematosus
Hypertension, February 1, 2007; 49(2): e13 - e13.
[Full Text] [PDF]